BioAtla Inc. (NASDAQ:BCAB) went up by 8.07% from its latest closing price compared to the recent 1-year high of $26.20. The company’s stock price has collected 6.49% of gains in the last five trading sessions. Barron’s reported on 12/16/20 that IPO of AI Lending Firm Upstart Gains 47%
Is It Worth Investing in BioAtla Inc. (NASDAQ :BCAB) Right Now?
Opinions of the stock are interesting as 6 analysts out of 7 who provided ratings for BioAtla Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $27.71, which is $18.2 above the current price. BCAB currently public float of 31.49M and currently shorts hold a 12.82% ratio of that float. Today, the average trading volume of BCAB was 558.51K shares.
BCAB’s Market Performance
BCAB stocks went up by 6.49% for the week, with a monthly jump of 38.43% and a quarterly performance of 2.81%, while its annual performance rate touched -62.44%. The volatility ratio for the week stands at 7.89% while the volatility levels for the past 30 days are set at 9.98% for BioAtla Inc. The simple moving average for the period of the last 20 days is 21.03% for BCAB stocks with a simple moving average of 69.95% for the last 200 days.
Analysts’ Opinion of BCAB
Many brokerage firms have already submitted their reports for BCAB stocks, with JMP Securities repeating the rating for BCAB by listing it as a “Mkt Outperform.” The predicted price for BCAB in the upcoming period, according to JMP Securities is $17 based on the research report published on September 15th of the current year 2022.
Credit Suisse, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $5, previously predicting the price at $35. The rating they have provided for BCAB stocks is “Neutral” according to the report published on May 05th, 2022.
H.C. Wainwright gave a rating of “Buy” to BCAB, setting the target price at $25 in the report published on March 21st of the current year.
BCAB Trading at 22.45% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.70% of loss for the given period.
Volatility was left at 9.98%, however, over the last 30 days, the volatility rate increased by 7.89%, as shares surge +41.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.14% upper at present.
During the last 5 trading sessions, BCAB rose by +6.49%, which changed the moving average for the period of 200-days by +23.03% in comparison to the 20-day moving average, which settled at $8.00. In addition, BioAtla Inc. saw -51.55% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at BCAB starting from MCBRINN SYLVIA, who purchase 2,000 shares at the price of $8.27 back on Nov 22. After this action, MCBRINN SYLVIA now owns 5,425 shares of BioAtla Inc., valued at $16,540 using the latest closing price.
MCBRINN SYLVIA, the Director of BioAtla Inc., purchase 1,000 shares at $8.20 during a trade that took place back on Sep 13, which means that MCBRINN SYLVIA is holding 3,000 shares at $8,200 based on the most recent closing price.
Stock Fundamentals for BCAB
Current profitability levels for the company are sitting at:
- -38576.00 for the present operating margin
- -432.00 for the gross margin
The net margin for BioAtla Inc. stands at -38160.80. Equity return is now at value -57.80, with -46.10 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 12.48.